Hermab 440mg injection (Trastuzumab)|Breast cancer treatment|MHP
HERMAB 440MG
DESCRIPTION
Hermab 440mg injection be expressed by a targeted cancer drug known as Trastuzumab, which is Pharmacologically classify as humanized monoclonal antibody produced by recombinant DNA technology.Hermab 440mg helps to decrease the rate of reactivation & mortality..
One of the epidermal growth factor receptors is known as human epidermal growth factor receptor 2 (HER2) plays vital role in breast cancer. This factor is responsible for cell replication..
An FDA approved product Hermab 440mg injection which is involved in breast cancer treatment.
Hermab 440mg vial with 858mg of lyophilized powder containing 440mg of Trastuzumab
 |
| HERMAB 440mg |
 |
| gastric cancer |
INDICATION
The drug Hermab 440mg is used for the treatment of Supportive treatment for breast cancerThe drug Hermab 440mg is used for the treatment of Advanced breast cancer
The drug Hermab 440mg is used for the treatment of Advanced gastric cancer
MECHANISM OF ACTION
Hermab 440mg injection is a type of monoclonal antibody which targeting the HER2, provoke a resistant mediate reaction which causes disguise and down regulation of HER2.HER2 pathway is specific for cell proliferation, joining of Transtuzumab to the site of HER2 causes prevention of this activity. This joining leads to antibody mediated and leads to HER2 positive cells break down.
Hermab 440mg is a intermediary of anti-body dependent cellular cytotoxicity.
PRODUCT DETAILS
Brand : HermabIngredients : Trastuzumab
Strength : 440mg
Manufactured : RPG Life Sciences
Package : 1 injection in 1 vial
PHARMACOKINETICS
DISTRIBUTION
Volume of distribution: 44 mL/kg as trastuzumab; 3.13 L as trastuzumab emtansine.METABOLISM
As trastuzumab emtansine: which Undergoes deconjugation and catabolism through proteolysis in cellular lysosomes.EXCRETION
Terminal Elimination half-life is 6 days (weekly dosing); 16 days (3 weekly regimen); approx. 4 days as trastuzumab emtansineELIMINATION
Elimination of drug includes clearance of IgG through the reticuloendothelial system.DOSAGE MANAGEMENT
Adjuvant regimen for HER2 over expressing Breast cancer52 weeks of treatment total schedules as follows
• Combination With paclitaxel or docetaxel, over a 90 minutes, 4mg/kg IV then over 30 minutes , 2mg /kg for 12 weeks or combination with Carboplatin/ docetaxel for 18 weeks one week following the last weekly dose.
• Over 30 to 90 minutes, 6mg/kg IV for every 3 weeks.
Esophageal carcinoma or gastric cancer for adult dose
• 8mg/kg IV over 90 minutes as initial dose
• 6mg/kg IV over 30 to 90 minutes for every 3 weeks as maintenance dose
• Duration of therapy for initial and maintenance dose until disease progression.
Breast cancer Metastatic HER2-Overexpressing
• Over 90 minutes, 4mg/kg alone or with combination of paclitaxel in initial dose.
• Over 30 minutes, 2mg /kg once in a week for maintenance dose.
• Duration of therapy for initial and maintenance dose until disease progression.
Administration
Hermab 440mg injection is administer into vein through IV infusion over 90 minutes
Do not administer IV push or bolus.
Duration of Hermab 440mg injection is administrated in once every week or every 3 weeks.
Before starting treatment, patients should undergo biopsy to check Hermab 440mg is the right regimen the infusion solution should be compatible to polyvinyl chloride or polyethylene bags.
After dilution, the infusion bag should be stored at 2oC to 8oC for not more than 24 hours before use.
PRECAUTONS
Embryo fetal damageHermab 440mg is contraindicated to pregnancy period.
Avoid becoming pregnancy during this therapy.
Use efficient contraceptives during treatment
Cardiomyopathy
Hermab 440mg receiving patients have increased risk of exposing to cardiac disorders.
Provide alternative therapy management
In serious condition, treatment should be discontinuing
Pulmonary toxicity
Some serious fatal cases of pulmonary toxicity occur during Hermab 440mg treatment.
Infusion reactions
During Hermab 440mg injection treatment some life-threatening infusion reactions are produced.
In serious infusion reactions, Stop the Hermab 440mg injection treatment permanently.
Patient should be treated with premedication before starting the infusion to overcome the such problem
During Hermab 440mg treatment. Use with Caution.
Therapy induced neutropenia
Higher incidence of neutropenia occurs during Hermab 440mg treatment.
SIDE EFFECTS
The most common adverse effects
Cardiomyopathy, Infusion reactions, Embryo fetal toxicity, Pulmonary toxicity, Chemotherapy induced neutropenia.The most common side effects
Hypertension, Influenza, Dyspnea, URI, Rhinitis, Pharyngolaryngeal pain, Sinusitis, Epitasis, Pulmonary hypertension, Dizziness, Decrease LVEF, Palpitations, Arrhythmia, Cardiac failure, Cough, Interstitial pneumonitis, Diarrhea/constipation, Nausea, vomiting, Dyspepsia, Autoimmune thyroiditis, Neutropenia, Hypokalemia, Anemia, Thrombocytopenia, Febrile neutropenia, Renal failure, Abdominal pain, Arthralgia, Back pain, Bone pain, Headache, Paresthesia, Rash, Nail disorders, Pruritus, Pyrexia, Chills, Edema, Asthenia, Sudden death.
PREGNANCY:
Hermab 440mg pregnancy category is D: Hermab 440mg injection should not suggest during pregnancy condition
LACTATION :
Breast feeding should not be recommended.
STORAGE :
Hermab 440mg vials should be stored at refrigerator temperature of 2°C to 8°C
Keep the vial away from heat & light
After reconstitution, vial should be stored at 2°C to 8°C for 28 days.
Stored Hermab 440mg injection diluted bag at 2°C to 8°C for 24 hours
MISSED DOSE
If missed cycles of Hermab 440mg treatment by one week or less, then the repeated maintenance dose (weekly schedule: 2mg/kg; 3 weekly schedules: 6mg/kg) administer as soon as probably.Until the next planned cycle, the patient does not take interval.
Consecutive Hermab 440mg maintenance dose should be taken in 7 days or 21 days next confer to the weekly or 3 weekly schedules.
If patient missed to take Hermab 440mg injection dose by higher than one week, then resume with re-storing dose of Hermab 440mg such as weekly schedule is 4mg/kg; 3 weekly schedules is 8mg/kg should be administered over period of 90 minutes.
CONTACT DETAILS
EMAIL: millionhealthpharmaceuticals@gmail.com
PHONE NO:+91-9940472902
Comments
Post a Comment